Enalaprilum [Inn-Latin] en es it fr


Enalaprilum [Inn-Latin] Les marques, Enalaprilum [Inn-Latin] Analogs

Enalaprilum [Inn-Latin] Les marques melange

  • Vaseretic (Enalapril Maleate + Hydrochlorothiazide)
  • Enalaprilum [Inn-Latin] Formule chimique


    Enalaprilum [Inn-Latin] RX lien


    Enalaprilum [Inn-Latin] FDA fiche

    Enalaprilum_[Inn-Latin] FDA

    Enalaprilum [Inn-Latin] msds (fiche de securite des materiaux)

    Enalaprilum [Inn-Latin] Synthese de reference

    A. Patchett et al., Nature 288, 280 (1980)

    Enalaprilum [Inn-Latin] Poids moleculaire

    376.447 g/mol

    Enalaprilum [Inn-Latin] Point de fusion


    Enalaprilum [Inn-Latin] H2O Solubilite


    Enalaprilum [Inn-Latin] Etat


    Enalaprilum [Inn-Latin] LogP


    Enalaprilum [Inn-Latin] Formes pharmaceutiques

    Tablet; injection IV

    Enalaprilum [Inn-Latin] Indication

    Pour le traitement de l'hypertension et l'insuffisance cardiaque. Il peut être utilisé seul ou en association avec des diurétiques thiazidiques.

    Enalaprilum [Inn-Latin] Pharmacologie

    L'énalapril, un enzyme convertissant l'angiotensine (IECA), est une prodrogue qui, une fois hydrolysé par estarases à son énalaprilate actif, est utilisé pour traiter l'hypertension et l'insuffisance cardiaque, de réduire la protéinurie et la maladie rénale chez les patients avec des néphropathies, et à prévenir les AVC, infarctus du myocarde et décès d'origine cardiaque à haut risque des patients. L'énalapril et l'énalaprilate inhibent l'enzyme de conversion (ACE) chez des sujets humains et les animaux. ACE est une peptidyl-dipeptidase qui catalyse la conversion de l'angiotensine I à la substance vasoconstrictrice, l'angiotensine II. L'angiotensine II stimule également l'aldostérone la sécrétion par le cortex surrénalien.

    Enalaprilum [Inn-Latin] Absorption


    Enalaprilum [Inn-Latin] Toxicite


    Enalaprilum [Inn-Latin] Information pour les patients

    Angioedema: Angioedema, including laryngeal edema, may occur at any time during treatment with angiotensin converting enzyme inhibitors, including enalapril. Patients should be so advised and told to report immediately any signs or symptoms suggesting angioedema (swelling of face, extremities, eyes, lips, tongue, difficulty in swallowing or breathing) and to take no more drug until they have consulted with the prescribing physician.

    Hypotension: Patients should be cautioned to report lightheadedness, especially during the first few days of therapy. If actual syncope occurs, the patients should be told to discontinue the drug until they have consulted with the prescribing physician.

    All patients should be cautioned that excessive perspiration and dehydration may lead to an excessive fall in blood pressure because of reduction in fluid volume. Other causes of volume depletion such as vomiting or diarrhea may also lead to a fall in blood pressure; patients should be advised to consult with the physician.

    Hyperkalemia: Patients should be told not to use salt substitutes containing potassium without consulting their physician. Neutropenia: Patients should be told to report promptly any indication of infection (e.g., sore throat, fever) which may be a sign of neutropenia.

    Pregnancy: Female patients of childbearing age should be told about the consequences of second- and third-trimester exposure to ACE inhibitors, and they should also be told that these consequences do not appear to have resulted from intrauterine ACEinhibitor exposure that has been limited to the first trimester. These patients should be asked to report pregnancies to their physicians as soon as possible.

    NOTE: As with many other drugs, certain advice to patients being treated with enalapril is warranted. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.

    Enalaprilum [Inn-Latin] Organismes affectes

    Les humains et autres mammifères